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Objective
To encourage the development of drugs for rare dis-
eases, an orphan drug legislation has been introduced in
the USA (1983) and in the EU (2000). Recent literature
provides criticism on the slow development of orphan
drugs in the EU. This study aims at identifying predic-
tors for successful marketing authorisation of potential
orphan drugs in the EU and the US.
Methods
Using publicly available data, the number of orphan des-
ignations and orphan drugs in the EU and the US was
determined. A comparison between randomly selected
authorised and a matched sample of not yet authorised
orphan drug designations in the EU has been per-
formed. Determinants in the study included characteris-
tics of the indication, of the product and of the sponsor.
Results
More orphan drugs were developed in the US during the
first ten years of the US Orphan Drug Act (1983-1992,
N=73) and during the first ten years of the EU Regulation
on Orphan Medicinal products (2000-2009, N=112) than
in the EU (2000-2009, N=59). Orphan drug approval was
strongly associated with previous experiences of the
sponsor in obtaining approval for another orphan drug
(OR=17.3, 95% CI=5.6-53.1). Furthermore, existing syn-
thetic entities compared to biotechnology products
tended to have a higher likelihood of reaching approval
status (OR=3.9, 95% CI=0.9-16.6).
Conclusion
This study showed that the experience of a company in
developing orphan drugs is an important predictor for
subsequent authorisation of other orphan drugs. The
same applies for existing (synthetic) molecules, for
which more knowledge is available. Companies or insti-
tutions wishing to develop an orphan drug should there-
fore seek experienced assistance and engage in dialogue
with the regulatory authorities.
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